- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Foster City Today
By the People, for the People
Gilead Sciences Stock Holdings Boosted by Nisa Investment Advisors
Institutional investor increases stake in biopharmaceutical company by over 30%
Apr. 1, 2026 at 10:34am
Got story updates? Submit your updates here. ›
Nisa Investment Advisors LLC, an institutional investor, grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 31.5% during the fourth quarter, according to the company's recent 13F filing with the SEC. The investor now owns 481,741 shares of the biopharmaceutical company's stock, valued at $59,129,000.
Why it matters
This increase in Gilead Sciences' institutional ownership signals confidence from major investors in the company's long-term growth potential, particularly in its antiviral therapies and expanding pipeline of treatments.
The details
Nisa Investment Advisors added 115,465 shares of Gilead Sciences to its portfolio during the fourth quarter. The firm's total holdings in the biopharmaceutical company are now valued at $59,129,000. Several other large institutional investors, including Moody Lynn & Lieberson LLC and Fifth Third Wealth Advisors LLC, also increased their positions in Gilead Sciences during the same period.
- Nisa Investment Advisors filed its 13F report for the fourth quarter on January 15, 2026.
- The reported increase in Gilead Sciences holdings occurred between October 1 and December 31, 2025.
The players
Nisa Investment Advisors LLC
An institutional investment firm that manages a portfolio of stocks, bonds, and other assets on behalf of its clients.
Gilead Sciences, Inc.
A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, including antiviral therapies, oncology, cell therapy, and inflammatory diseases.
The takeaway
The increased institutional investment in Gilead Sciences reflects the company's strong position in the biopharmaceutical industry and the confidence of major investors in its ability to deliver long-term growth and shareholder value.
